Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Oct 26, 2026
Sunshine Biopharma Inc. (SBFM)
A forensic read on Sunshine Biopharma Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-1.6
Distress distance
Clean
Earnings quality
4
Forensic signals
-25.7%
ROE
4.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Sunshine Biopharma Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -1.6, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
188d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 128 to 188 FY2024→FY2025 (against cost of goods sold; inventory +19% vs -1% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-33.8%
FY2025
Return on invested capital.Return on invested capital is -33.8% in the latest fiscal year and rising across FY2023–FY2025 from -68.7%. After-tax operating profit was ($4M) in FY2023 and ($5M) in FY2025, with operating income at -19.9% of revenue in FY2023, -16.7% in FY2024 and -17.2% in FY2025. The capital base behind it cannot be compared across FY2023–FY2025: long-term debt is tagged in one of those two fiscal years and not the other, and an untagged line enters this calculation as zero, so any change in the base would be a change in what the filer tagged.
stopped
FY2024→FY2025
Shareholder returns — halted.Capital returns have STOPPED — $3M of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash.
-$26.6M
FY2023–FY2025
Cash burn vs. reported loss.Over FY2023–FY2025, the company reported a cumulative net loss of $15.6M against operating cash flow of -$26.6M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.
Key fundamentals
Latest Revenue$36.3M
Revenue Growth YoY+4.1%
Revenue CAGR (2yr)+22.8%
Net Margin-16.5%
Free Cash Flow-$5.5M
Return on Equity-25.7%
Debt / Equity0.00x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Sunshine Biopharma Inc.'s actual 10-K/10-Q/8-K filings?